pdufa.bio
Home › Decisions › LNTH 2026-03-06

LNTH FDA decision — Mar 6, 2026

✓ APPROVED

Lantheus Holdings Inc. — PYLARIFY TruVu (piflufolastat F 18) Injectio · Prostate Cancer.

Run-up into the decision (T-120 → T+5)

PDUFA 3/6/26$78.84$50.119/19/25
Daily close, T-120 (9/19/25) through T+5. Run-up high $78.84 on 3/3/26, low $50.11 on 9/29/25 (T-120 to T-1). FDA decision 3/6/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-06
OutcomeApproved
Drug / candidatePYLARIFY TruVu (piflufolastat F 18) Injectio
CompanyLantheus Holdings Inc.
120-day run-up (T-120→T-1)+44.1%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio